Updated with recent data on mavacamten from ESC Paris, 2019.
Two San Francisco based companies are now conducting clinical trials for three drugs specifically targeting HCM.
MyoKardia, which was founded in 2012 by a group of HCM researchers (including Stanford’s James Spudich, one of the founders of Cytokinetics – the second company conducting a HCM drug trial – see below), was the first entrant into the HCM area with the development of its drug, mavacamten (formerly known as MYK-461).
Mavacamten is currently the subject of the Phase 3 EXPLORER-HCM clinical trial for obstructive HCM, now fully enrolled with results expected in 2020, as well as the Phase 2 MAVERICK-HCM trial for non-obstructive HCM, with results are expected later this year.
And, MyoKardia announced this week that it is will begin testing a second drug for HCM. The new drug, currently known as MYK-224, is the subject of a new Phase 1 clinical trial. This drug targets the sarcomeric…
View original post 239 more words